Evotec SE

Correction of a release from 11/07/2024, 14:16 CET/CEST – Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Evotec and Pfizer collaborate to advance drug discovery in France

Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz

Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program

Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb

Evotec SE: Results of the Annual General Meeting 2024

Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases

Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease

Evotec reports Q1 2024 results and provides corporate update

Evotec SE to announce results for first quarter 2024 on 22 may 2024

Evotec SE: Dr. Cord Dohrmann, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2023 pursuant Evotec’s remuneration system.